In this position, Mr Lytton will be responsible for leading the company’s business development activities. From 2001 to 2009, Mr Lytton served as a general partner at Oxford Bioscience Partners, a venture capital firm.
Hans Hasler, COO of Biogen Idec, said: “Michael brings more than 25 years of business development, investment and legal experience in the biotechnology industry. His M&A background, as well as his experience in identifying and translating promising science into successful companies, makes him uniquely qualified to build on our track record of highly disciplined and productive business development.”